New boron liposomes that contribute to medical treatment

A carborane-phospholipid complex addresses the limitations of current boron delivery agents by improving boron uptake and stability in tumor cells, enhancing the efficacy of Boron Neutron Capture Therapy and diagnostic imaging.

JP2024542261APending Publication Date: 2024-11-13PEKING UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024530544
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-22
Filing Date
2022-11-08
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Current boron delivery agents for Boron Neutron Capture Therapy (BNCT) face issues such as insufficient boron content, biotoxicity, immunogenicity, and structural instability of liposome encapsulation, limiting therapeutic efficacy and clinical application.

Method used

Development of a carborane-phospholipid complex with specific structural features, including a carborane group enriched with 10B, which is incorporated into a liposomal composition for targeted drug delivery, enhancing boron accumulation in tumor cells.

Benefits of technology

The carborane-phospholipid complex improves boron uptake in tumor cells, stabilizes liposome structure, and enhances therapeutic efficacy by allowing for effective neutron capture therapy and diagnostic imaging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542261000001_ABST
    Figure 2024542261000001_ABST
Patent Text Reader

Abstract

The present invention provides a carborane-phospholipid conjugate in which a carborane group is introduced at the end of one lipid arm of a phospholipid, and also provides a liposome composition comprising the carborane-phospholipid conjugate and its use for delivering at least one therapeutic agent and / or at least one diagnostic agent.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention claims priority to Chinese Application No. 202111391620.9, filed on November 22, 2021, the entire disclosure of which is incorporated by reference into this application.

[0002] The present invention relates to the medical and diagnostic fields, and specifically to novel boron liposomes that contribute to clinical practice. [Background technology]

[0003] Li J, Tu Z, Liu Z et al., An Unusual Direction Entering Dawn: A Brief Introduction to the Development History of Boron Carriers, Scientia Sinica Chimica. 2020, 50: 1296-1319, review, described boron carriers used in boron neutron capture therapy (BNCT). BNCT is a two-dimensional, cellular-scale, highly targeted, and high-energy radiation therapy with excellent killing effect on locally invasive malignant tumors such as melanoma, glioma, and recurrent head and neck cancer. The cell killing power of BNCT comes from the use of non-radioactive isotopes. 10 B captures low-energy thermal neutrons and then generates fission reactions, resulting in alpha particles and recoils. 7 They generate Li nuclei, which have high linear energy transfer and high efficacy relative to living organisms, can cause lethal damage to cells, and have limited penetrating ability (5-9 μm, about one cell diameter), limiting their destructive power to the scale of a single cell. 10 B(n, α) 7 To maintain the Li capture reaction, a large amount of 10 When B atoms selectively accumulate in tumor cells and absorb sufficient neutrons, BNCT can provide significant killing power to malignant tumors with little effect on nearby normal tissues. One effective therapy for malignant tumors is to deliver sufficient amounts of boron to the tumor site and then perform neutron irradiation.

[0004] The currently widely used boron delivery agent is 4-dihydroxyboryl-L-phenylalanine (BPA), but it has drawbacks such as insufficient boron content, which limits its therapeutic effect, and the selection of abnormal borane can lead to biological toxicity and immunogenicity. At the same time, the encapsulation and delivery of drugs by liposomes has the problem that the encapsulation structure is easily damaged. In the actual treatment process, doctors need to make timely diagnoses for patients, but the current BNCT drugs have a single function and can only meet the needs of treatment, which limits their clinical application. Summary of the Invention [Problem to be solved by the invention]

[0005] Under these circumstances, it is desirable to find new raw materials and synthesize molecules with new structures to solve the above problems. [Means for solving the problem]

[0006] The present invention provides a carborane-phospholipid conjugate having a structure represented by formula (I): [ka] (In the formula, one of R1 and R2 is an -L-carborane group, and the other is a linear alkyl or alkenyl group having 10 to 24 carbon atoms, L is a divalent linking group, and X is -H, -CH 2 CH 2 NH 3 , -CH 2 CH 2 N + (CH 3 ) 3 , -CH 2 CH(NH 2 )COOH, -CH 2 CH(OH)CH 2 OH, or cyclohexane-2,3,4,5,6-pentahydroxy-1- group, and Y is OH or O - It is.)

[0007] In one embodiment of the present invention, the carborane group in the -L-carborane group is 10 B enriched. In one embodiment of the present invention, X is -CH 2 CH 2 N + (CH 3 ) 3 and Y is O - It is. In a preferred embodiment of the present invention, the lipid arm comprising R1 or R2, respectively, satisfies one, two or three of the following conditions, preferably satisfies all three conditions simultaneously: (1) The difference in length is within ±1A. (2) The distance between the lipid arms is within 5A; (3) The dihedral angle is within 5 degrees.

[0008] In one embodiment of the invention, the carborane group is a 1,2-C 2 B 4 H 5 -,1,2-C 2 B 8 H 9 -,1,2-C 2 B 10 H 11 -,2,3-C 2 B 4 H 7 -,7,8-C 2 B 9 H 12 - or 5,6-C 2 B 8 H 11 -, preferably 1,2-C 2 B 10 H 11 -It is.

[0009] In one embodiment of the present invention, L is -(CH 2 ) n+m -, -(CH 2 ) n+m -S-, -(CH 2 ) n+m -O-, -(CH 2 ) n -CH=CH-(CH 2 )m -, -(CH 2 ) n -CH=CH-(CH 2 ) m -S-, -(CH 2 ) n -CH=CH-(CH 2 ) m -O-, -(CH 2 ) n -S-(CH 2 ) m -, -(CH 2 ) n -S-(CH 2 ) m+1 -S-, -(CH 2 ) n -O-(CH 2 ) m -, -(CH 2 )nO-(CH 2 ) m+1 -O-, -(CH 2 ) n -N(CH 3 )-(CH 2 ) m - or -(CH 2 ) n -N(CH 3 )-(CH 2 ) m+1 -N(CH 3 )-, where n is an integer from 1 to 20, and m is an integer from 0 to 20. For example, the carborane-phospholipid conjugate represented by formula (I) has the following structure: [ka] wherein Bo is a carborane group and n is an integer from 1 to 20. In one embodiment, Bo is a 1,2-C 2 B 10 H 11 -, preferably a closo-dicarbadodecaborane group, and more preferably a closo-1,2-dicarbadodecaborane group, in which n is 3, 7, 11 or 15, and preferably 11.

[0010] Another aspect of the invention provides a liposome composition comprising the above-described carborane-phospholipid complex, which is part of a lipid bilayer.

[0011] In one embodiment of the invention, the liposome composition further comprises cholesterol.

[0012] In one embodiment of the present invention, the liposome composition further comprises a phospholipid, preferably dilauroylphosphatidylcholine (DLPC), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dimyristoylphosphatidylglycerol (DMPG), distearoylphosphatidylglycerol (DSPG), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG). , dimyristoyl phosphatidylserine (DMPS), distearoyl phosphatidylserine (DSPS), dioleoyl phosphatidylserine (DOPS), dipalmitoyl phosphatidylserine (DPPS), dioleoyl phosphatidylethanolamine (DOPE), dipalmitoyl phosphatidylethanolamine (DPPE), dimyristoyl phosphatidylethanolamine (DMPE), distearoyl phosphatidylethanolamine (DSPE) or dielaidoyl phosphatidylethanolamine, more preferably DPPC.

[0013] In one embodiment of the invention, the liposome composition further comprises a PEGylated phospholipid, such as DLPE-PEG, DPPE-PEG, DMPE-PEG or DSPE-PEG, preferably DSPE-PEG.

[0014] In one embodiment of the invention, the liposome composition further comprises at least one therapeutic agent and / or at least one diagnostic agent.

[0015] In a preferred embodiment, the liposome composition comprises at least one therapeutic agent, and the therapeutic agent is an anticancer agent.For example, the anticancer agent is selected from monomethyl auristatin E, monomethyl auristatin F, ibrutinib, acalabrutinib, zanubrutinib, doxorubicin, mitomycin-C, mitomycin-A, daunorubicin, aminopterin, actinomycin, bleomycin, 9-aminocamptothecin, N8-acetylspermidine, 1-(2-chloroethyl)-1,2-dimethanesulfonylhydrazide, Yunnanmycin, gemcitabine, cytarabine, dolastatin, dacarbazine, 5-fluorouracil, paclitaxel, docetaxel, gemcitabine, cytarabine, 6-mercaptopurine, vincristine, cisplatin, oxaliplatin, and PARP inhibitor. In one embodiment, the anticancer drug is selected from PARP inhibitors, preferably olaparib, niraparib, rucaparib, fluzoparib, pamiparib, veliparib, talazoparib, more preferably olaparib.

[0016] In a preferred embodiment of the invention, the liposome composition comprises at least one diagnostic agent, said diagnostic agent being 64 Cu-NOTA-PEG2000-DSPE.

[0017] Yet another aspect of the present invention provides the use of the liposome composition in medicine.

[0018] A further aspect of the invention provides the use of said liposomal composition for delivering at least one therapeutic agent and / or at least one diagnostic agent. [Brief description of the drawings]

[0019] In order to more specifically describe the embodiments of the present invention, the drawings of the embodiments are briefly described below. Obviously, the drawings in the following description relate to some embodiments of the present invention and are not intended to limit the scope of the present invention. [Figure 1] The structure of novel boron liposomes and the strategy for drug encapsulation are presented. [Diagram 2] The change in tumor volume in mice under different drug conditions encapsulated in boron liposomes (Dox: doxorubicin, PARPi: polyadenosine diphosphate ribose polymerase (PARP) inhibitor olaparib, and N: neutron irradiation) is shown. [Diagram 3] Imaging of boron liposomes using a transmission electron microscope (TEM). [Figure 4] Whole-body maximum density projection PET images of a 4T1 tumor-bearing mouse 12 h after intravenous injection of 64Cu-NOTA-boron liposomes. The tumor is surrounded by a white dotted coil. [Diagram 5] A cross-section of the BoP-1 membrane structure simulated by molecular dynamics. [Figure 6] A cross-section of the BoP-2 membrane structure simulated by molecular dynamics. [Figure 7] A cross-section of the BoP-3 membrane structure simulated by molecular dynamics is shown. [Figure 8] A cross-section of the BoP-4 membrane structure simulated by molecular dynamics. [Figure 9] A cross-section of the DPPC membrane structure simulated by molecular dynamics. [Figure 10] The results of measuring the UV-vis absorption of BoPs and DPPC with SRB encapsulated are shown. [Figure 11] The results of measuring the leakage percentage of SRB after 24 hours of incubation at 37° C. in 50% bovine serum protein are shown. [Figure 12] 4 shows the boron uptake in 4T1 cells after 24 h incubation with different concentrations of boron liposomes. [Figure 13] The activity of 4T1 cells incubated with different concentrations of boron liposomes for 24 hours is shown. [Figure 14] The mean tumor volumes of mice in the PARP inhibitor-boron liposome and PARP inhibitor-boron liposome+N treated groups (n=9) (paired t-test, **p<0.01) are shown. [Figure 15] The average body weight (n=9) of mice in each group treated with boron liposome+N or PARP inhibitor-boron liposome+N is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] In order to make the objectives, technical solutions and advantages of the embodiments of the present invention clearer, the invention of the embodiments of the present invention will be described clearly and completely below with reference to the drawings of the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, but not all embodiments. Based on the described embodiments of the present invention, all other embodiments obtained by those skilled in the art without requiring creative efforts are also included in the scope of protection of the present invention.

[0021] The present invention may be embodied in other specific forms without departing from the essential characteristics of the present invention. Any and all embodiments of the present invention may be combined with technical features of other embodiments or multiple other embodiments, unless inconsistent, to obtain additional embodiments. The present invention includes the additional embodiments obtained by such combinations.

[0022] Unless otherwise defined, technical or scientific terms used herein have the ordinary meaning as understood by one of ordinary skill in the art to which this invention belongs.

[0023] In this specification, the use of similar words such as "comprises," "contains," or "consisting of" means that the elements appearing before the word include the elements listed after the word, and equivalents thereof, without excluding other elements.

[0024] Unless otherwise specified in the examples or otherwise, all numerical values ​​indicating amounts of ingredients, reaction conditions, durations, quantitative properties of ingredients, and the like, set forth in the specification and claims are to be understood in all instances to be modified by the term "about." Also, any numerical range recited herein is intended to include all subranges of that range and any combination of the endpoints of that range or subrange, for example, the integer 1 to 20 includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20, as well as subranges 1 to 3, 1 to 4, 1 to 10, 2 to 4, 2 to 10, etc.

[0025] The present invention should be construed in accordance with the laws and principles of chemical bonding. Hydrogen atoms may be removed to introduce substituents at given positions.

[0026] In the present invention, the phospholipid is a glycerophospholipid, which is a derivative of a compound such as a fatty acid (e.g., capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, erucic acid), glycerol, and phosphoric acid, in which two hydroxyl groups in glycerol are replaced with fatty acids, and another hydroxyl group is replaced with phosphoric acid and other groups, and the hydrophilic phosphoric acid group and the two hydrophobic lipid arm ends are linked via a glycerol molecule. In the present invention, the phospholipid may be a natural phospholipid or a synthetic phospholipid. Exemplary phospholipids include, but are not limited to, phosphatidic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, and phosphatidylinositol.

[0027] In the present invention, a carborane-phospholipid conjugate refers to a phospholipid derivative in which a carborane group is introduced at the end of one of the lipid arms of a phospholipid.

[0028] One aspect of the present invention provides a carborane-phospholipid conjugate represented by formula (I): [ka] One of R1 and R2 is an -L-carborane group, the other is a linear alkyl or alkenyl group having 10 to 24 carbon atoms, L is a divalent linking group, and X is -H, -CH 2 CH 2 NH 3 , -CH 2 CH 2 N + (CH 3 ) 3 , -CH 2 CH(NH 2 )COOH, -CH 2 CH(OH)CH 2 OH, or cyclohexane-2,3,4,5,6-pentahydroxy-1- group, and Y is OH or O - It is.

[0029] In the present invention, the carborane-phospholipid complex has a carborane introduced into one lipid arm of a phospholipid, and its structure is similar to the phospholipid structure of cells, and therefore has good compatibility with cells.

[0030] Carborane is a type of polyhedral boron-carbon molecular cluster compound. In the present invention, the carborane group refers to a group in which a hydrogen atom has been lost from a C-H bond of carborane.

[0031] In one embodiment of the present invention, a carborane group is obtained by loss of a hydrogen atom from a C-H bond of a carborane as follows: [ka]

[0032] In other words, the carborane group is a 1,2-C 2 B 4 H 5 -,1,2-C 2 B 8 H 9 -,1,2-C 2 B 10 H 11 -,2,3-C 2 B 4 H7 -,7,8-C 2 B 9 H 12 - or 5,6-C 2 B 8 H 11 -It is.

[0033] In a preferred embodiment, the carborane group is obtained by the loss of a hydrogen atom to a C-H bond of a carborane containing 8 to 11 boron atoms. In a more preferred embodiment, the carborane group is dicarba-closo-dodecaborane C 2 B 10 H 12 ) by the loss of a hydrogen atom from the C–H bond, i.e., 1,2-C 2 B 10 H 11 -It is.

[0034] The boron atom in the carborane / carborane group of the present invention may consist of naturally occurring boron element; 10 In one embodiment, one or more boron atoms in the carborane / carborane group may be: 10 B enriched, e.g., carborane / carborane groups 10 The B abundance is greater than 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96% or 97%, and even greater than 98% or 99%. 10 B-enriched carboranes are 10 B-enriched boric acid may be prepared as a raw material or may be commercially available from Katchem spol.s ro, Czech Republic (http: / / :www.katchem.cz / en).

[0035] In one embodiment, at least one boron atom in the carborane / carborane group is 10 It's B.

[0036] In one embodiment, the boron atom in the carborane-phospholipid complex is 10For example, at least one boron atom in the carborane-phospholipid complex is 10 It's B.

[0037] In one embodiment, the compound of general formula (I) 10 of one or more boron atoms in the B-enriched complex 10 The B abundance ratio is greater than 30%, 40%, 50%, 60%, 70% or 80%, preferably greater than 90%, 95%, 96% or 97%, and even more preferably greater than 98% or 99%. 10 The abundance ratio of B is the ratio of other boron atoms 10 The abundance ratio of B may be the same as or different from that of B.

[0038] In one embodiment, the compound of general formula (I) 10 per boron atom in the B-enriched complex 10 The abundance of B is greater than 90%.

[0039] In this case, X is -H, -CH 2 CH 2 NH 3 , -CH 2 CH 2 N + (CH 3 ) 3 , -CH 2 CH(NH 2 )COOH, -CH 2 CH(OH)CH 2 Carborane-phospholipid complexes with OH or cyclohexane-2,3,4,5,6-pentahydroxy-1-groups are derivatives of phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, and phosphatidylinositol, respectively.

[0040] In one embodiment, X is -CH 2 CH 2 N + (CH 3 ) 3 and Y is O -i.e., the carborane-phospholipid complex is a phosphatidylcholine derivative.

[0041] In the present invention, the difference in length between lipid arms refers to the distance from the carboxyl group C at the tip of R1 to the non-H atom at the end of R1 minus the distance from the carboxyl group C at the tip of R2 to the non-H atom at the end of R2.

[0042] In the present invention, the distance between the lipid arms is the distance between the first C adjacent to the glycerol group of R1 and the first C adjacent to the glycerol group of R2 in the compound of general formula (I).

[0043] In the present invention, the dihedral angle between lipid arms refers to the dihedral angle formed by the non-H atom at the end of R1, the carboxyl group C at the tip of R1, the carboxyl group C at the tip of R2, and the non-H atom at the end of R2.

[0044] In one embodiment of the carborane-phospholipid conjugate of the invention, the two lipid arms, each comprising R1 or R2, satisfy one, two or three of the following conditions:

[0045] The difference in length is within ±3A.

[0046] The distance between the lipid arms is within 15A;

[0047] The dihedral angle is within 15 degrees.

[0048] In one embodiment of the carborane-phospholipid conjugate of the invention, the two lipid arms, each comprising R1 or R2, satisfy one, two or three of the following conditions:

[0049] The difference in length is within ±2A.

[0050] The distance between the lipid arms is within 10A,

[0051] The dihedral angle is within 10 degrees.

[0052] In a preferred embodiment of the carborane-phospholipid complex of the present invention, the two lipid arms each containing R1 or R2 satisfy one, two or three of the following conditions: the difference in length is within ±1 A; the distance between the lipid arms is within 5 A; and the dihedral angle is within 5 degrees. In a more preferred embodiment of the carborane-phospholipid complex of the present invention, the three conditions are preferably satisfied simultaneously.

[0053] Among R1 and R2, one is a linear alkyl or alkenyl group having 10 to 24 carbon atoms. In one embodiment, the linear alkyl or alkenyl group contains 11, 13, 15, 17, 19, 21, or 23 carbon atoms.

[0054] As used herein, the term "alkyl group" refers to a linear or branched saturated hydrocarbon chain group consisting of only n carbon atoms and 2n+1 hydrogen atoms. For example, 10 -C 24 An alkyl group refers to a linear or branched saturated hydrocarbon chain group of 10 to 24 carbon atoms. For example, the numerical range "10 to 24" refers to each integer within the given range, e.g., "10 to 24 carbon atoms" indicates that the alkyl group contains 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 carbon atoms. A linear alkyl group refers to an alkyl group that does not have a branched chain, e.g., a decyl group (C 10 H 21 -), lauryl group (C 12 H 25 -), myristyl group (C 14 H 29 -), palmityl group (C 16 H 33 -), stearyl group (C 18 H 37 -), eicosyl group (C 20 H 41 -), docosyl group (C 22 H 45 -) or tetracosyl (C 24 H 49 -).

[0055] In the present invention, the alkenyl group refers to a straight or branched hydrocarbon chain group consisting of only carbon and hydrogen atoms and containing at least one double bond (for example, one or two double bonds). For example, cis-9-tetradecenyl group, trans-9-tetradecenyl group, cis-9-hexadecenyl group, trans-9-hexadecenyl group, cis-9-octadecenyl group, trans-9-octadecenyl group, cis-11-octadecenyl, cis,cis-9,12-octadecadienyl group, trans,trans-9,12-octadecadienyl group, cis-13-docosenyl, etc. The straight alkenyl group refers to an alkenyl group that does not have a branched chain.

[0056] L is a divalent linking group. In a preferred embodiment, L is a group having a flexible hydrophobic chain. In a more preferred embodiment, L is equivalent to the hydrophobicity and flexibility of the non-carborane lipid arm in the carborane-phospholipid complex. For example, L is -(CH 2 ) n+m -, -(CH 2 ) n+m -S-, -(CH 2 ) nm -O-, -(CH 2 ) n -CH=CH-(CH 2 ) m -, -(CH 2 ) n -CH=CH-(CH 2 ) m -S-, -(CH 2 ) n -CH=CH-(CH 2 ) m -O-, -(CH 2 ) n -S-(CH 2 ) m -, -(CH 2 ) n -S-(CH 2 ) m+1 -S-, -(CH 2 ) n -O-(CH 2 ) m -, -(CH 2 )nO-(CH 2 )m+1 -O-, -(CH 2 ) n -N(CH 3 )-(CH 2 ) m - or -(CH 2 ) n -N(CH 3 )-(CH 2 ) m+1 -N(CH 3 )-, where n is an integer from 1 to 20 and m is an integer from 0 to 20. In one specific embodiment, L is -(CH 2 ) n+m -S-, where n is an integer of 1 to 20 and m is an integer of 0 to 20, for example, L is -(CH 2 ) 12 -S-, -(CH 2 ) 13 -S-, -(CH 2 ) 14 -S-, -(CH 2 ) 15 -S-, -(CH 2 ) 16 -S-, -(CH 2 ) 17 -S-, -(CH 2 ) 18 -S-, -(CH 2 ) 19 -S-, -(CH 2 ) 20 -S-, -(CH 2 ) 21 -S-, -(CH 2 ) 22 -S-, -(CH 2 ) 23 -S- or -(CH 2 ) 24 -S-.

[0057] In a preferred embodiment, L has no branching.

[0058] In a preferred embodiment of the invention, the carborane-phospholipid conjugate has the structure: [ka] Here, Bo represents a carborane group, and n is an integer of 1 to 20. In a more preferred embodiment of the present invention, Bo is a 1,2-C 2 B 10 H 11 -, preferably a closo-dicarbadodecaborane group, more preferably a closo-1,2-dicarbadodecaborane group, and n is 3, 7, 11 or 15, preferably 11.

[0059] Synthesis of carborane-phospholipid conjugates

[0060] In the present invention, a carborane-phospholipid conjugate can be obtained by synthesizing a C-substituted carborane derivative, such as a carborane group -L-COOH, and a lysophospholipid in the presence of a dehydrating agent, such as dicyclohexylcarbodiimide (DCC), in the presence of a catalyst, such as 4-dimethylaminopyridine (DMAP).

[0061] Synthesis of C-substituted carborane derivatives

[0062] Due to the strong electron-withdrawing property of the cage structure of carborane, the H in the C-H bond exhibits weak acidity, and a series of C-substituted carborane derivatives can be obtained by reacting with strong bases such as alkyllithium reagents. For example, carborane can be reacted with oxetane, ethylene oxide, or formaldehyde under the action of butyllithium to give -CH 2 CH 2 CH 2 OH, -CH 2 CH 2 OH, -CH 2 OH groups can be introduced into carboranes.

[0063] The carborane group -L-COOH is the carborane group -L-CH 2 OH, CrO 3 It can be obtained by oxidation with an oxidizing agent such as

[0064] The carborane derivatives may be mono- or doubly substituted. In a preferred embodiment, the resulting carborane derivatives are mono-substituted.

[0065] Carborane derivatives can be synthesized using t-butyldimethylsilyl (TBDMS) or triphenylsilyl as the C-Top protecting group. For example, mono- or doubly substituted carborane derivatives can be synthesized using triphenylsilyl as the C-Top protecting group. [ka] For the synthesis of C-substituted carborane derivatives, see the review article "Research Progress on Synthesis of Carborane Derivatives" by Juyou Lu et al., Synthetic Chemistry, 2015, 23(9):883, and "A new series of organoboranes III: Some reactions of 1,2-dicarbaclovododecaborane(12) and its derivatives, Inorganic Chemistry," 1963, 2:1097-1105, He YT, Ager J, Clark S et al.

[0066] Synthesis of lysophospholipids

[0067] In the synthesis method of the present invention, commercially available or homemade lysophospholipids can be used. Lysophospholipids can be produced by enzymatic hydrolysis of phospholipids, and the 1-acyl group can be converted to lysophospholipids by phospholipase A. 1 The 2-acyl group is hydrolyzed by phospholipase A. 2 The lysophospholipids used include, for example, lysophosphatidylcholine, lysophosphatidic acid, lysophosphatidylethanolamine, lysophosphatidylserine, lysophosphatidylinositol, etc. In one embodiment, the lysophospholipid used is lysophosphatidylcholine (Lyso-PPC).

[0068] For specific preparation methods of lysophospholipids, see the review by Zhao Li et al., ChiNaOils and Fats, 2018, 43(6):132-143. Phospholipids for hydrolysis may be commercially available or may be synthesized as needed.

[0069] The synthesis of carborane-phospholipid conjugates will be explained below using compounds BoP 1-4 as examples. [ka] Chemical synthesis route of compound BoP

[0070] Liposomes

[0071] Another aspect of the present invention provides a liposomal composition comprising the above-described carborane-phospholipid complex which is part of a lipid bilayer.

[0072] The liposomes of the present invention may be unilamellar, i.e. composed of a single lipid bilayer, and have a diameter ranging from about 20 nm to about 400 nm.The liposomes of the present invention may be multilamellar, and have a diameter generally ranging from 1 μm to 10 μm.

[0073] The liposome of the present invention has a cell membrane-like structure, and therefore has a high affinity for cells, and can improve the permeability of the active ingredient (therapeutic agent and / or diagnostic agent) to cells, thereby improving the concentration and action of the active ingredient at the disease site. Since the active ingredient is encapsulated in the liposome, the diffusion rate in tissues is reduced, the release rate into the blood is slowed, and the time during which the active ingredient acts is extended. Under the protection of the liposome bilayer, the active ingredient is protected from oxidation, decomposition, or destruction by acids or enzymes in the human body, and the stability of the active ingredient can be ensured or maintained.

[0074] In one embodiment of the present invention, the liposome composition further comprises cholesterol.It is believed that cholesterol can strengthen lipid bilayer membrane, reduce the fluidity of phospholipid bilayer membrane, reduce membrane permeability, and reduce leakage of active ingredient.At the same time, it can maintain a certain flexibility of lipid membrane, and enhance the ability of liposome vesicle to resist changes in external conditions.It also has a certain protective effect against the oxidation of phospholipid.

[0075] In one embodiment of the present invention, the liposome composition further comprises a phospholipid, and preferably a saturated phospholipid. Examples of phospholipids include dilauroyl phosphatidylcholine (DLPC), dimyristoyl phosphatidylcholine (DMPC), distearoyl phosphatidylcholine (DSPC), dioleoyl phosphatidylcholine (DOPC), dipalmitoyl phosphatidylcholine (DPPC), dimyristoyl phosphatidylglycerol (DMPG), distearoyl phosphatidylglycerol (DSPG), dioleoyl phosphatidylglycerol (DOPG), dipalmitoyl phosphatidylglycerol (DPPG), dimyristoyl phosphatidylserine (DMPS), Examples of suitable phospholipids include distearoyl phosphatidylserine (DSPS), dioleoyl phosphatidylserine (DOPS), dipalmitoyl phosphatidylserine (DPPS), dioleoyl phosphatidylethanolamine (DOPE), dipalmitoyl phosphatidylethanolamine (DPPE), dimyristoyl phosphatidylethanolamine (DMPE), distearoyl phosphatidylethanolamine (DSPE), didaidoyl phosphatidylethanolamine, hydrogenated soy phosphatidylcholine (HSPC), and the like, preferably DPPC. In a preferred embodiment, the phospholipid contained in the liposome composition is similar to the phospholipid structure in the carborane-phospholipid complex of formula I, i.e., has the same or similar R1 or R2 (e.g., carbon chain length difference within 1), and the same or similar X and Y. It is believed that the addition of a phospholipid can improve the stability of the bilipid molecule and reduce the amount of the carborane-phospholipid complex used.

[0076] In one embodiment of the present invention, the liposome composition further comprises a PEGylated phospholipid. The PEGylated phospholipid is obtained by covalently binding a PEG molecule to a phospholipid molecule to form a PEG-derivatized phospholipid, which is believed to be capable of lowering the leakage rate of liposomes, reducing their aggregation and fusion, prolonging their effective period, inhibiting cell adhesion in the systemic circulation, masking the recognition and uptake of liposomes by the RES, and prolonging the cycle time of liposomes in the body. The molecular weight of PEG in the PEGylated phospholipid is usually about 500 to about 5000 daltons (Da; g / mol), for example, a molecular weight of 750 Da, 1000 Da, 2000 Da, or 5000 Da. The PEG in the PEGylated phospholipid may have a linear or branched structure.

[0077] In one embodiment of the present invention, the PEGylated phospholipid is preferably DLPE-PEG, DPPE-PEG, DMPE-PEG or DSPE-PEG, more preferably DSPE-PEG, such as DSPE-PEG2000 and DSPE-PEG5000.

[0078] In one embodiment of the invention, the liposome composition comprises both cholesterol and phospholipids.

[0079] In one embodiment of the present invention, the liposome composition simultaneously comprises cholesterol, phospholipid and PEGylated phospholipid. In a preferred embodiment of the present invention, the liposome composition simultaneously comprises cholesterol, phospholipid and PEGylated phospholipid, and the difference between the lipid arms of the phospholipid and the PEGylated phospholipid is 0, 1 or 2 carbon atoms.

[0080] The liposomes of the present invention may further comprise pharma- ceutically acceptable formulation auxiliary agents, such as stabilizers, antioxidants, pH adjusters, flavoring agents, carriers, diluents, excipients, etc. Pharmaceutically acceptable means that the formulation auxiliary agent must be compatible with the other components of the formulation and is harmless to the subject to which the formulation is administered. In the present invention, the subject means a mammal, and may be a human or a pet.

[0081] In one embodiment of the present invention, the liposome composition further comprises at least one therapeutic agent and / or at least one diagnostic agent. The therapeutic or diagnostic agent may be encapsulated in the aqueous compartment of the liposome or may be incorporated into the lipid bilayer. As shown in Figure 1, water-soluble chemotherapeutic agents may be encapsulated in the aqueous compartment of liposomes composed of boronated phospholipids.

[0082] Suitable molecules that can be used as therapeutic agents include, but are not limited to, polypeptides, oligopeptides, peptoids, amino acids, enzyme inhibitors, hormones, toxins, antibiotics, anti-inflammatory substances, anti-cancer drugs, immune inhibitors, bronchodilators, and the like.

[0083] In a preferred embodiment, the liposome composition comprises at least one therapeutic agent, said therapeutic agent being an anti-cancer agent.

[0084] The therapeutic agent may be, for example, antimetabolites (e.g., folate antagonists (e.g., methotrexate), fluoropyrimidines (e.g., 5-fluorouracil), purine and adenosine analogs, cytarabine), intercalating antitumor antibiotics (e.g., anthracyclines (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, mycemycin-C, dactinomycin, and mithramycin-C), hramycin), platinum derivatives (e.g., cisplatin and carboplatin), alkylating agents (e.g., nitrogen mustard, melphalan, chlorambucil, busulfan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa, antimitotics (e.g., vinca alkaloids (e.g., vincristine) and taxanes (e.g., paclitaxel, docetaxel)) and the newer microtubule agents. The therapeutic agent may be an anti-inflammatory agent (e.g., epothilone analogs, dispersmolide analogs, and eleutherobin analogs), a topoisomerase inhibitor (e.g., epipodophyllotoxins (e.g., etoposide, teniposide, ansacholin, and topotecan)), a cell cycle inhibitor (e.g., flavopyridol), a biological response modifier, and a proteasome inhibitor (e.g., bortezomib)).

[0085] For example, the anticancer drug is selected from monomethyl auristatin E, monomethyl auristatin F, ibrutinib, acalabrutinib, zanubrutinib, doxorubicin, mitomycin-C, mitomycin-A, daunorubicin, aminopterin, actinomycin, bleomycin, 9-aminocamptothecin, N8-acetylspermidine, 1-(2-chloroethyl)-1,2-dimethanesulfonylhydrazide, Yunnanmycin, gemcitabine, cytarabine, dolastatin, dacarbazine, 5-fluorouracil, paclitaxel, docetaxel, gemcitabine, cytarabine, 6-mercaptopurine, vincristine, cisplatin, oxaliplatin, and PARP inhibitors.

[0086] In one embodiment, the anticancer drug is selected from PARP inhibitors, preferably olaparib, niraparib, rucaparib, fluzoparib, pamiparib, veliparib, talazoparib, more preferably olaparib.

[0087] The liposomes of the present invention may contain a diagnostic agent. Diagnostic agents used in the present invention include any diagnostic agent known in the art, as provided by the following references: Armstrong et al., Diagnostic Imaging, 5th Edition, Blackwell Publishing (2004); Torchilin, VP, ed., Targeted Delivery of Imaging Agents, CRC Press (1995); Vallabhajosula, S., Molecular Imaging: Radiopharmaceuticals for PET and SPECT, Springer (2009). Diagnostic agents can be detected by a variety of means, including agents that provide and / or enhance detectable signals, including, but not limited to, gamma-emitting signals, radioactive signals, echogenic signals, optical signals, fluorescent signals, absorption signals, magnetic signals, or tomographic signals.

[0088] Techniques for imaging diagnostic agents include, but are not limited to, single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), optical imaging, positron emission tomography (PET), computed tomography (CT), x-ray imaging, gamma imaging, etc. The diagnostic agents can be attached to the therapeutic liposomes by a variety of methods, including, for example, being embedded or encapsulated in the liposomes.

[0089] In some embodiments, diagnostic agents may include chelating agents that bind metal ions and are used in a number of diagnostic imaging techniques. Examples of chelating agents include, but are not limited to, ethylenediaminetetraacetic acid (EDTA), [4-(1,4,8,11-tetraazacyclotetradecan-1-yl)methyl]benzoic acid (CPTA), cyclohexanediaminetetraacetic acid (CDTA), ethylene glycol bis(2-aminoethyl ether)tetraacetic acid (EGTA), diethylenetriaminepentaacetic acid (DTPA), citric acid, hydroxyethylethylenediaminetriacetic acid (HEDTA), iminodiacetic acid (IDA), triethylenetetraminehexaacetic acid (TTHA), 1,4,7,10-tetraazacyclododecane 1,4,7,10-tetrakis(methylenephosphonic acid) (DOTP), 1,4,8,11-tetraazacyclododecane 1,4,8,11-tetraacetic acid (TETA), 1,4,7,10-tetraazacyclododecane 1,4,7,10-tetraacetic acid (DOTA) and derivatives thereof.

[0090] Radioisotopes may be incorporated into some of the diagnostic agents described herein and may include radionuclides that emit gamma rays, positrons, beta and alpha particles, and X-rays. Suitable radionuclides include 225 Ac, 72 As, 211 At, 11 B. 128 Ba, 212 Bi, 75 Br, 77 Br, 14 C. 109 Cd, 62 Cu, 64 Cu, 67Cu, 18 F, 67 Ga, 68 Ga, 3 H, 123 I, 125 I, 130 I, 131 I, 111 In, 177 Lu, 13 N, 15 O. 32 P, 33 P, 212 Pb, 103 Pd, 186 Re, 188 Re, 47 Sc, 153 Sm, 89 Sr, 99m Tc, 88 y and 90 In some embodiments, the radioactive reagent includes, but is not limited to, 111 In-DTPA, 99m Tc(CO) 3 -DTPA, 99m Tc(CO) 3 -ENPy 2 , 62 / 64 / 67 Cu-TETA, 99m Tc(CO) 3 -IDA, and 99m Tc(CO) 3 In another embodiment, the reagent comprises DOTA and 111 In, 177 Lu, 153 Sm, 88 / 90 y, 62 / 64 / 67 Cu, or 67 / 68Various analogs with Ga are included. In some embodiments, the liposomes may be radiolabeled, for example by incorporating lipids conjugated to chelators such as DTPA lipids, as provided in the following references: Phillips et al., Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 1 (1): 69-83 (2008); Torchilin, VP & Weissig, eds., Liposomes 2nd ed.: Oxford Univ. Press, Eur. J. Med. Mol. Imaging 33:1196-1205(2006); Mougin-Degraef, M.

[0091] In other embodiments, the diagnostic agent may include optical reagents such as fluorescent agents, phosphorescent agents, chemiluminescent agents, etc. A variety of reagents (e.g., dyes, probes, labels, or indicators) are known in the art and may be used in the present invention. (See, e.g., Invitrogen, The Handbook-A Guide to Fluorescent Probes and Labeling Technologies, 10th Edition (2005)). Fluorescent agents may include organic and / or inorganic small molecules or fluorescent proteins and their derivatives. For example, fluorescent agents include, but are not limited to, cyanines, phthalocyanines, porphyrins, indigo, rhodamines, phenoxazines, phenylxanthenes, phenothiazines, phenoselenazines, fluoresceins, benzoporphyrins, squaliums, dipyrrolopyrimidine ketones, tetracenes, quinolines, pyrazines, corrins, croconiums, acridones, phenanthridines, rhodamines, acridines, anthraquinones, chalcogenides, and the like. These include chalcogenopyrylium analogues, chlorines, naphthalocyanines, methinedyes, indolenium dyes, azo compounds, chamomile blue, azachamomile blue, triphenylmethane dyes, indoles, benzoindoles, indolecarbocyanines, benzindolecarbocyanines, and BODIPY TM derivatives having the general structure of 4,4-difluoro-4-boron-3a,4a-diaza-s-indacene derivatives, and / or complexes and / or derivatives thereof.Other reagents that may be used include, but are not limited to, fluorescein, fluorescein-polyaspartic acid conjugate, fluorescein-polyglutamic acid conjugate, fluorescein-polyarginine conjugate, indigo green, indigo-aspartic acid conjugate, indigo-polyaspartic acid conjugate, isosulfan blue, indole disulfonates, benzindole disulfonates, bis(ethylcarboxymethyl)indigo, bis(pentylcarboxymethyl)indigo, polyhydroxyindole sulfonates, polyhydroxybenzoindole sulfonates, hard heteroatom indole sulfonates, indigo dipropionic acid, indigo biscaproic acid, 3,6-dicyano-2,5-[(N,N,',N'-tetrakis(carboxymethyl)amino] Pyrazine, 3,6-[(N,N,',N'-tetrakis(2-hydroxyethyl)amino]pyrazine-2,5-dicarboxylic acid, 3,6-bis(N-azetidinyl(azatedino))pyrazine-2,5-dicarboxylic acid, 3,6-bis(N-morpholino)pyrazine-2,5-dicarboxylic acid, 3,6-bis(N-piperazino)pyrazine-2,5-dicarboxylic acid, 3,6-bis(N-thiomorpholino)pyrazine-2,5 -dicarboxylic acid, 3,6-bis(N-thiomorpholino)pyrazine-2,5-dicarboxylic acid S-oxide, 2,5-dicyano-3,6-bis(N-thiomorpholino)pyrazine S,S-dioxide, indocarbocyaninetetrasulfonate, chloroindolecarbocyanine, and 3,6-diaminopyrazine-2,5-dicarboxylic acid.

[0092] In a preferred embodiment of the present invention, the liposome composition comprises 64 Contains at least one diagnostic agent which is Cu-NOTA-PEG2000-DSPE.

[0093] The liposomes of the present invention can be prepared by methods commonly used in the art, such as injection method (ethanol injection method and ethyl ether injection method), thin film dispersion method, reverse phase evaporation method, chemical gradient method (pH gradient method, ammonium sulfate gradient method, calcium acetate gradient method), multiple emulsion method, freeze-drying method, etc., see Chinese Journal of Pharmacopoeia, Vol. 46, No. 14, pp. 1084-1088, 2011.

[0094] In one embodiment, blank liposomes containing ammonium sulfate solution are prepared by the ethanol injection method or thin film dispersion method, and then an ammonium sulfate gradient is formed after removing the external ammonium sulfate from the liposome membrane, and liposomes carrying therapeutic or diagnostic agents are formed by the ammonium sulfate gradient method.

[0095] The particle size of the liposome of the present invention can be measured by a thermodynamic light scattering method, for example, using a Zetasizer 3000SH laser particle size analyzer (Malvern Instruments Ltd), and the diameter is mainly about 20 to about 150 nm.

[0096] The encapsulation efficiency of the liposome of the present invention can be measured by a centrifugation method, a dialysis method, a gel column chromatography method, or the like.

[0097] The liposomes according to the present invention can be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or locally) as needed, and the amount administered varies depending on the patient's weight, age, sex, health condition, diet, injection time, injection method, excretion rate and disease severity. For example, the liposomes according to the present invention can be administered intravenously, pulmonary (atomized inhalation or dry powder inhalation), or dermal, as needed. The amount administered is about 0.1-10 mg / kg body weight of the therapeutic or diagnostic agent contained in the liposomes. EXAMPLES

[0098] The starting materials of the examples are commercially available and / or can be prepared by various methods well known to those skilled in the art of organic synthesis. Those skilled in the art of organic synthesis will appropriately select the reaction conditions (including solvents, reaction atmosphere, reaction temperature, duration of the experiment and post-treatment) in the following synthetic methods. Those skilled in the art of organic synthesis will understand that the functional groups present on each part of the molecule should be compatible with the proposed reagents and reactions. NMR was recorded using a Bruker AVANCE 400MHz spectrometer. High-resolution mass spectra were measured using a Bruker Fourier Transform Ion Cyclotron resonant mass spectrometer. The LC / MS used was a Waters e2695 equipped with a Waters 2995 PDA and a Waters Acquity QDA mass spectrometer.

[0099] 1. Chemical synthesis of a series of BoPs

[0100] A series of BoPs (BoP 1-4) were synthesized using the above synthetic route, among which the number of methylene groups in the carbon chain is n=3, 7, 11, 15, and the corresponding compounds are numbered in ascending order, with a total yield of 11%-20% and a purity of >97%.

[0101] The specific synthesis procedure and characterization method of BoP-3 are as follows:

[0102] (1) Chemical synthesis of carborane mercaptotriethylamine salt (1):

[0103] The substrate (o-carborane, 1.00 g, 6.93 mmol) was dissolved in THF (30 mL) and cooled to 0° C. under anhydrous and oxygen-free conditions. n-Butyl lithium (4.4 mL, 6.93 mmol) was added dropwise to the solution over 15 min and stirred for 30 min. The system was then allowed to return to room temperature for 30 min. Sublimed sulfur (225 mg, 6.93 mmol) was added and reacted under ice-water bath conditions for 30 min. The system was then allowed to return to room temperature for 30 min. The solution was spin-dried to obtain a yellow liquid. Hydrochloric acid (1 M, 7 mL) was then added to quench the unreacted n-butyl lithium. The solution was extracted with n-hexane, washed successively with water and saturated saline, and spin-dried. Triethylamine (1 mL, 7.18 mmol) was added dropwise to the n-hexane solution (6 mL) of the above product under room temperature conditions and stirred for 15 min. After a white precipitate was formed, it was filtered off with suction, washed three times with 6 ml of n-hexane, and dried in air.

[0104] (2) Preparation of carborane fatty acid: 1-HOOC(CH 2 ) 11 5 mL of concentrated sulfuric acid was added dropwise to a solution of Br (9.3 mmol) in ethanol (50 mL), stirred at room temperature for 15 minutes, and heated to reflux for 12 hours. The mixture was cooled and spin-dried. Ethyl acetate (30 mL) and water (30 mL) were added for extraction, washed with pure water and saturated saline, and then dissolved in anhydrous Na 2 SO 4 The crude product was subjected to column chromatography on a silica gel column using petroleum ether and ethyl acetate as eluents. After the solvent was removed by spin drying under reduced pressure, 1-C 2 H 5 OC(O)(CH 2 ) 11 To a solution of 1 (1.86 mmol) in ethanol (42 mL), Br(CH 2 ) 11 C(O)OC 2 H 5(1.86 mmol) was added, stirred at room temperature for 15 minutes, and heated for 16 hours. The reaction mixture was cooled and then spin-dried. The residue was extracted with ethyl acetate (30 mL) and washed with pure water (30 mL). After separating the organic phase, it was washed with water and saturated saline, and then anhydrous Na 2 SO 4 The crude product was subjected to column chromatography on a silica gel column. The solvent was removed by spin drying under reduced pressure, and 1-C 2 H 5 OC(O)(CH 2 ) 11 S-1,2-C 2 B 10 H 11 This was dissolved in glacial acetic acid (29 mL) to form a colorless, transparent solution. After stirring at room temperature for 15 minutes, pure water (9.8 mL) and concentrated sulfuric acid (9.8 mL) were added dropwise in sequence for hydrolysis for 16 hours to obtain 1-HOOCC(O)(CH 2 ) 11 S-1,2-C 2 B 10 H 11 (2) was obtained.

[0105] (3) Preparation of BoP-3: Dicyclohexylcarbodiimide (DCC, 2.6 equiv.) and 4-dimethylaminopyridine (DMAP, 4.0 equiv.) were added to a 0.1M solution of carborane-group fatty acid (carbon number 12, 2) (2.0 equiv.) in chloroform. The solution was stirred at room temperature for 5 min. Lyso-PPC (1.3 equiv.) was added and the reaction was stirred for 24 h. The reaction mixture was concentrated using a rotary evaporator. Column chromatography (65:25:4 CH 2 Cl 2 :MeOH:H 2 O) to obtain BoP-3.

[0106] (4) Characterization of BoP-3: By molecular dynamics simulation, the conformation of the membrane structure consisting of BoPs with different carbon numbers (BoP-1, BoP-2, BoP-3, BoP-4, etc.) was observed, and it was found that the conformation of BoP-3 was the most stable, the degree of long chain folding was the smallest, and it was closest to the membrane structure by DPPC (Figure 5-Figure 9). At the same time, the drug loading efficiency was tested, sulforhodamine B (SRB) was encapsulated, and the absorption at 550 nm was measured, and it was found that the degree of absorption of BoP-3 was the highest (Figure 10), indicating that the membrane structure is the most complete. At the same time, the leakage status of SRB was measured, and it was found that the SRB leakage percentage of BoP-3 was the smallest after 24 h incubation in 50% bovine serum under the condition of 37 ° C (Figure 11). At the same time, it was characterized by means of nuclear magnetic resonance hydrogen spectrum, showing an accurate structure. In order to obtain more intuitive information on the membrane structure formed by BoP-3, boron liposomes consisting of BoP-3, DPPC, cholesterol and DPPE-PEG2000 were prepared and observed by transmission electron microscopy (TEM). The results showed that the particle size was controlled by an extruder and the boron liposomes were spherical carriers with a diameter of 30-100 nm, with regular shapes and almost no damage (see Figure 3). The polydispersity index and zeta potential (ζ potential) of this spherical carrier were measured simultaneously, and after doxorubicin (Dox) was encapsulated, the electrical neutrality reached -3.1 mV, indicating effective drug loading performance.

[0107] BoP-1, BoP-2, BoP-4 Manufacturing:

[0108] BoP-1, BoP-2, and BoP-4 are almost identical to the preparation of BoP-3, except for the carbon chain length of the bromo carboxylic acid selected when first synthesizing the carborane fatty acid. The substrate for BoP-1 is 1-HOOC(CH 2 ) 3 Br, the substrate for BoP-2 is 1-HOOC(CH 2 ) 7 Br, the substrate for BoP-4 is 1-HOOC(CH 2 ) 15 Br. The details are as follows:

[0109] (1) BoP-1:1-HOOC(CH 2 ) 3 5 mL of concentrated sulfuric acid was added dropwise to a solution of Br (9.3 mmol) in ethanol (50 mL), stirred at room temperature for 15 minutes, and heated under reflux for 12 hours. The mixture was cooled and spin-dried. Ethyl acetate (30 mL) and water (30 mL) were added for extraction, washed with pure water and saturated saline, and then dissolved in anhydrous Na 2 SO 4 The crude product was subjected to column chromatography on a silica gel column using petroleum ether and ethyl acetate as eluents. After the solvent was removed by spin drying under reduced pressure, 1-C 2 H 5 OC(O)(CH 2 ) 3 Br was obtained. To a solution of 1 (1.86 mmol) in ethanol (42 mL), Br(CH 2 ) 3 C(O)OC 2 H 5 (1.86 mmol) was added, stirred at room temperature for 15 minutes, and heated for 16 hours. The reaction mixture was cooled and then spin-dried. The residue was extracted with ethyl acetate (30 mL) and washed with pure water (30 mL). After separating the organic phase, it was washed with water and saturated saline, and then anhydrous Na 2 SO 4 The crude product was subjected to column chromatography on a silica gel column. The solvent was removed by spin drying under reduced pressure, and 1-C 2 H 5 OC(O)(CH 2 ) 3 S-1,2-C 2 B 10 H 11 This was dissolved in glacial acetic acid (29 mL) to form a colorless, transparent solution. After stirring at room temperature for 15 minutes, pure water (9.8 mL) and concentrated sulfuric acid (9.8 mL) were added dropwise in sequence for hydrolysis for 16 hours to give 1-HOOCC(O)(CH 2 ) 3 S-1,2-C 2 B 10 H 11(3) was obtained by adding dicyclohexylcarbodiimide (DCC, 2.6 equiv.) and 4-dimethylaminopyridine (DMAP, 4.0 equiv.) to a 0.1M solution of carborane-based fatty acids (carbon numbers 4 and 3) (2.0 equiv.) in chloroform. The solution was stirred at room temperature for 5 min. Lyso-PPC (1.3 equiv.) was added and the reaction was stirred for 24 h. The reaction mixture was concentrated using a rotary evaporator. Column chromatography (65:25:4 CH 2 Cl 2 :MeOH:H 2 O) to obtain BoP-1.

[0110] (2) BoP-2:1-HOOC(CH 2 ) 7 5 mL of concentrated sulfuric acid was added dropwise to a solution of Br (9.3 mmol) in ethanol (50 mL), stirred at room temperature for 15 minutes, and heated to reflux for 12 hours. The mixture was cooled and spin-dried. Ethyl acetate (30 mL) and water (30 mL) were added for extraction, washed with pure water and saturated saline, and then dissolved in anhydrous Na 2 SO 4 The crude product was subjected to column chromatography on a silica gel column using petroleum ether and ethyl acetate as eluents. After the solvent was removed by spin drying under reduced pressure, 1-C 2 H 5 OC(O)(CH 2 ) 7 Br was obtained. To a solution of 1 (1.86 mmol) in ethanol (42 mL), Br(CH 2 ) 7 C(O)OC 2 H 5 (1.86 mmol) was added, stirred at room temperature for 15 minutes, and heated for 16 hours. The reaction mixture was cooled and then spin-dried. The residue was extracted with ethyl acetate (30 mL) and washed with pure water (30 mL). After separating the organic phase, it was washed with water and saturated saline, and then anhydrous Na 2 SO 4 The crude product was subjected to column chromatography on a silica gel column. The solvent was removed by spin drying under reduced pressure, and 1-C 2 H 5 OC(O)(CH2 ) 7 S-1,2-C 2 B 10 H 11 This was dissolved in glacial acetic acid (29 mL) to form a colorless, transparent solution. After stirring at room temperature for 15 minutes, pure water (9.8 mL) and concentrated sulfuric acid (9.8 mL) were added dropwise in sequence for hydrolysis for 16 hours to give 1-HOOCC(O)(CH 2 ) 7 S-1,2-C 2 B 10 H 11 (4) was obtained by adding dicyclohexylcarbodiimide (DCC, 2.6 equiv.) and 4-dimethylaminopyridine (DMAP, 4.0 equiv.) to a 0.1M solution of carborane-based fatty acids (carbon numbers 8 and 4) (2.0 equiv.) in chloroform. The solution was stirred at room temperature for 5 min. Lyso-PPC (1.3 equiv.) was added and the reaction was stirred for 24 h. The reaction mixture was concentrated using a rotary evaporator. Column chromatography (65:25:4 CH 2 Cl 2 :MeOH:H 2 O) to obtain BoP-2.

[0111] (3) BoP-4:1-HOOC(CH 2 ) 15 5 mL of concentrated sulfuric acid was added dropwise to a solution of Br (9.3 mmol) in ethanol (50 mL), stirred at room temperature for 15 minutes, and heated to reflux for 12 hours. The mixture was cooled and spin-dried. Ethyl acetate (30 mL) and water (30 mL) were added for extraction, washed with pure water and saturated saline, and then dissolved in anhydrous Na 2 SO 4 The crude product was subjected to column chromatography on a silica gel column using petroleum ether and ethyl acetate as eluents. After the solvent was removed by spin drying under reduced pressure, 1-C 2 H 5 OC(O)(CH 2 ) 15 Br was obtained. To a solution of 1 (1.86 mmol) in ethanol (42 mL), Br(CH 2 ) 15 C(O)OC 2 H 5(1.86 mmol) was added, stirred at room temperature for 15 minutes, and heated for 16 hours. The reaction mixture was cooled and then spin-dried. The residue was extracted with ethyl acetate (30 mL) and washed with pure water (30 mL). After separating the organic phase, it was washed with water and saturated saline, and then anhydrous Na 2 SO 4 The crude product was subjected to column chromatography on a silica gel column. The solvent was removed by spin drying under reduced pressure, and 1-C 2 H 5 OC(O)(CH 2 ) 15 S-1,2-C 2 B 10 H 11 This was dissolved in glacial acetic acid (29 mL) to form a colorless, transparent solution. After stirring at room temperature for 15 minutes, pure water (9.8 mL) and concentrated sulfuric acid (9.8 mL) were added dropwise in sequence for hydrolysis for 16 hours to give 1-HOOCC(O)(CH 2 ) 15 S-1,2-C 2 B 10 H 11 (4) was obtained by adding dicyclohexylcarbodiimide (DCC, 2.6 equiv.) and 4-dimethylaminopyridine (DMAP, 4.0 equiv.) to a 0.1M solution of carborane-based fatty acids (carbon numbers 16 and 5) (2.0 equiv.) in chloroform. The solution was stirred at room temperature for 5 min. Lyso-PPC (1.3 equiv.) was added and the reaction was stirred for 24 h. The reaction mixture was concentrated using a rotary evaporator. Column chromatography (65:25:4 CH 2 Cl 2 :MeOH:H 2 O) to obtain BoP-4.

[0112] 2. Composition and preparation of boron liposomes

[0113] Distearoylphosphatidylcholine (DPPC), cholesterol (Chol), distearoylphosphatidylethanolamine-polyethylene glycol 2000 (DSPE-PEG 2k) and BoP with a total mass of 20 mg were dissolved in 1 mL of ethanol at 60° C. in a ratio of (BoP:DPPC:Chol:DSPE-PEG 2k=50:10:40:1, mol%), and then ammonium sulfate buffer (4 mL, 250 mM, pH=5.5) was injected at 60° C. Then, the liposome solution was passed through a liposome extruder at 60° C., the membrane pore size was set to 200 nm, and the liposome was pressed a total of 10 times. Then, the membrane was replaced with one with a membrane pore size of 100 nm, and the pressing was continued a total of 10 times. The liberated ammonium sulfate was dialyzed away in 800 mL of a solution consisting of 10% sucrose and 10 mM histidine (pH = 6.5), with the dialysate exchanged at least twice within 12 hours.

[0114] 3. Drug loading of boron liposomes

[0115] For the boron liposomes loaded with sulforhodamine (SRB), the lipids of the formulation were dissolved in ethanol, hydrated with 50 mM SRB, and sonicated at 45°C for 30 min. Doxorubicin (Dox) was loaded by the ammonium sulfate gradient method. Dox with a drug-lipid molar ratio of 1:8 was added to the liposome solution and incubated at 60°C for 1 h, and the SRB release rate (%SRB release rate = (A final -A initial ) / (A Triton-X-100 -A initial ) × 100% was defined as the absorbance, and the stability and sealing ability were evaluated.

[0116] 4. Characterization of boron liposomes (dynamic light scattering, zeta potential analysis, morphological examination, three-dimensional model construction)

[0117] Dynamic light scattering and zeta potential analysis were performed on a Malvern Zetasizer Nano ZS. Morphological examination of boron liposomes was performed by TEM at 200 kV (JEM-2100, JEOL, Japan). A drop of liposome solution was added to a copper mesh covered with an ultrathin carbon film and dried at room temperature for 10 min. Excess solution was removed before negative staining with uranyl acetate solution (4% w / v), followed by washing with water. The tertiary structures of BoPs were predicted using Spartan14 software after optimization with density functional theory / Becke, three-parameter, Lee-Yang-Parr and 6-31G* basis (DFT / B3LYP / 6-31G*). The carbon arm length I b Parameters such as the boron arm length Δl, the lipid arm length difference d, the lipid arm pitch θ, and the lipid arm dihedral angle (°) were measured and evaluated.

[0118] [Table 1]

[0119] 5. Radiolabeling of Boron Liposomes

[0120] Provided by Peking University Cancer Hospital 64 CuCl 2 was dissolved in 0.01 M hydrochloric acid. NOTA-boron liposomes were prepared according to the indicated components (BoP-3:DPPC:cholesterol:DSPE-PEG2k-NOTA=50:10:40:1, mol%). NaAc buffer (1 mL, pH=5.5, 0.2 M) was added to the boron liposome solution (100 μL, 0.5 mg / mL), 64 CuCl 2 (18.5MBq) at 37°C for 2 hours and eluted with PBS. 64 Cu-NOTA-boron liposomes were purified with radiochemical yields of over 90%.

[0121] In the selection of boron-containing molecules, carborane (C 2 B 10 H 12 ) was selected. Carborane has a high boron content and can provide a good BNCT effect. Therefore, a boronated acyl group (carboranized fatty acid) was attached to a phospholipid molecule (Lyso-PPC), and a Thiol-halo reaction was used instead of click chemistry to maintain the flexibility of the phospholipid. However, since carborane exists as a three-dimensional structure molecule, it is necessary to consider the effect of steric hindrance on the stability of lipid bilayer formation. Therefore, carboranized fatty acids of different lengths (the number of atoms of the carbon chain C is 4, 8, 12, and 16, respectively, and is not limited to the above carbon numbers in practical applications) were selected. First, the three-dimensional structures of BoPs with different carbon numbers were verified, and the lengths of the two lipid arms under conditions in which the carboranized fatty acid has different carbon numbers was compared using dipalmitoylphosphatidylcholine DPPC as a reference, and it was found that the difference in length of BoP-3 was the smallest, and even smaller than DPPC, which is helpful in forming the most stable membrane structure. It was found that BoP-3 was closest to DPPC in terms of other parameters, such as the distance between lipid arms and the dihedral angle. Based on this, molecular dynamics simulation was combined to simulate a bilayer system formed by 128 BoP-3 and DPPC molecules, and it was found that the membrane structure formed by BoP-3 was regularly arranged and the degree of chain folding deformation was small. At the same time, in the experimental aspect, the drug loading capacity of BoP-3 was measured, and the drug loading efficiency was evaluated by coating sulforhodamine B (SRB). The lipid was hydrated with a 50 mM solution and gel filtration was performed to obtain liposomes. It was found that BoP-3 had the highest absorption at 550 nm, which was close to the DPPC group. After 24 hours of incubation, the release of SRB was measured in 50% bovine serum at 37 °C to evaluate the stability. In conclusion, the nanostructure formed by BoP-3 has a high retention efficacy for SRB. Finally, BoP-3 (carbon chain with 12 C atoms) was obtained as the optimal structure for self-assembly.

[0122] PET imaging was performed by applying DSPE-PEG2000-NOTA as a chelator for the positron-emitting nuclide Cu-64. The NOTA-lipid was incorporated into boron liposomes and then incubated with an aqueous solution of Cu-64 ions. 64 The Cu-NOTA-boron liposomes were purified by gel filtration. The stability for 24 hours was verified by radioactive thin layer chromatography. Then, the radioactively labeled boron liposomes (7.4MBq, 150μL) were intravenously injected into 4T1 tumor-bearing mice, and PET-CT imaging was performed (Figure 4) to evaluate the biodistribution and tumor specificity of the boron liposomes in the mouse body, further demonstrating that the biodistribution (tumor / normal site ratio) of such novel boron liposomes in the body is acceptable. In the practice of clinical tumor treatment, this can be used to determine the location in the tumor, evaluate the therapeutic effect in real time, and further formulate a treatment plan.

[0123] The boron concentration of cells after incubation with boron liposomes was evaluated by ICP-OES. Mouse 3-negative breast cancer 4T1 cells were co-incubated with boron liposomes at concentrations of 0.1-10mg / mL for 24 hours, and the experiment showed that the intracellular boron concentration gradually increased with increasing incubation amount of boron liposomes (Figure 12). At a dose of 5mg / mL, the boron concentration in 4T1 cells reached 182.5ppm (n=4), which fully met the requirements for clinical BNCT.

[0124] Next, the cytotoxicity of boron liposomes was evaluated by CCK-8 method. As shown in Figure 13, 4T1 cells were incubated with different concentrations of boron liposomes for 24 hours, and the cell activity was measured. The experiment showed that when the incubation concentration reached 5mg / mL, the cells showed good tolerance to boron liposomes.

[0125] Based on the above studies, we carried out neutron irradiation experiments on 4T1 tumor-bearing mice using boron liposomes. 4T1 tumor-bearing mice were injected with PBS (400μL), boron liposomes (500mg / kg) or Dox-boron liposomes (500mg / kg) via the tail vein, and 12 hours later, the mice were anesthetized and fixed at the outlet of the slow neutron beam (@IHNI), with the head of the mouse oriented toward the center, and the tumor was exposed within the irradiation range of the thermal neutrons and irradiated at full power for 30 minutes, while the liver, spleen and intestines were located outside the irradiation field to avoid unnecessary damage.

[0126] In addition, the in vivo antitumor effect of PARPi-boron liposome-BNCT was investigated. The experiment showed that the tumor volume of the PARPi@BLNP (i.e., boron liposomes carrying PARPi and not neutron irradiation) group increased significantly with increasing days after treatment, while the average tumor volume of the PARPi@BLNP+N (i.e., boron liposomes carrying PARPi and neutron irradiation) group was reduced to one-fifth of the original volume (Figure 14), and the tumor suppression effect was superior to the remaining control groups.

[0127] In terms of chemotherapy integration, the encapsulated drug was first selected as doxorubicin, and it was found that it could eradicate some tumors, and the effect of chemotherapy-assisted boron liposome-BNCT treatment was initially verified. Next, based on the principle of BNCT, if an individual drug that disrupts the DNA replication process could be selected, the therapeutic effect could be further enhanced. Therefore, a polyadenosine diphosphate ribose polymerase (PARP) inhibitor (olaparib) was selected. At the same time, the interference with the DNA repair system was verified by the γ-h2ax staining method, and an in vivo experiment on 4T1 tumor-bearing mice showed that PARPi-boron liposomes had a better therapeutic effect than doxorubicin-boron liposomes (see Figure 2).

[0128] The contents of all references cited in the specification of this invention (including literature references, published patents, disclosed patent applications, and co-pending patent applications) are expressly incorporated herein by reference in their entirety. Unless otherwise defined, all technical and scientific terms used herein are accorded the meaning commonly known to those skilled in the art.

[0129] Moreover, all of the features disclosed herein may be combined in any combination. Also, each feature disclosed herein may be replaced by an alternative feature having the same, equivalent or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is merely an example of a series of equivalent or similar features.

[0130] As described above, the basic features of the present invention can be easily derived by those skilled in the art, and the present invention can be variously changed and modified to suit various applications and conditions without departing from the spirit and scope of the present invention. Therefore, other embodiments are also included in the appended claims.

Claims

1. The following formula (1): 【Chemistry 1】 A carborane-phospholipid complex having a structure represented by the formula: (In the formula, one of R1 and R2 is an -L-carborane group, the other is a linear alkyl or alkenyl group having 10 to 24 carbon atoms, L is a divalent linking group, and X is -H, -CH 2 CH 2 N.H. 3 , -CH 2 CH 2 N + (CH 3 ) 3 , -CH 2 CH(NH 2 ) COOH, -CH 2 CH(OH)CH 2 OH, or a cyclohexane-2,3,4,5,6-pentahydroxy-1- group, and Y is OH or O - It is.)

2. The carborane group in the -L-carborane group is 10 The complex of claim 1 which is enriched in B.

3. The X is —CH 2 CH 2 N + (CH 3 ) 3 and Y is O - The complex according to any one of claims 1 to 2,

4. The complex according to any one of claims 1 to 3, wherein the lipid arm containing R1 or R2, respectively, satisfies one, two or three of the following conditions, preferably satisfies all three conditions simultaneously: (1) The difference in length is within ±1A, (2) The distance between the lipid arms is within 5A; (3) The dihedral angle is within 5 degrees.

5. The carborane group is a 1,2-C 2 B 4 H 5 -, 1,2-C 2 B 8 H 9 -, 1,2-C 2 B 10 H 11 -, 2,3-C 2 B 4 H 7 -,7,8-C 2 B 9 H 12 - or 5,6-C 2 B 8 H 11 -, preferably 1,2-C 2 B 10 H 11 The complex according to any one of claims 1 to 4, wherein

6. The L is -(CH 2 ) n+m -, -(CH 2 ) n+m -S-, -(CH 2 ) n+m -O-, -(CH 2 ) n -CH=CH-(CH 2 ) m -, -(CH 2 ) n -CH=CH-(CH 2 ) m -S-, -(CH 2 ) n -CH=CH-(CH 2 ) m -O-, -(CH 2 ) n -S-(CH 2 ) m -, -(CH 2 ) n -S-(CH 2 ) m+1 -S-, -(CH 2 ) n -O-(CH 2 ) m -, -(CH 2 )n-O-(CH 2 ) m+1 -O-, -(CH 2 ) n -N(CH 3 )-(CH 2 ) m - or -(CH 2 ) n -N(CH 3 )-(CH 2 ) m+1 -N(CH 3 )-, preferably -(CH 2 ) n+m The complex of any one of claims 1 to 5, wherein -S-, n is an integer from 1 to 20, and m is an integer from 0 to 20.

7. The formula: 【Chemistry 2】 The complex of claim 6 having a structure represented by: (In the formula, Bo is a carborane group, and n is an integer from 1 to 20.)

8. The Bo is 1,2-C 2 B 10 H 11 -, preferably a closo-dicarbadodecaborane group, more preferably a closo-1,2-dicarbadodecaborane group, and n is 3, 7, 11 or 15, preferably 11.

9. The composite material according to any one of claims 1 to 8, A liposome composition, wherein the complex is part of a lipid bilayer.

10. The liposome composition of claim 9 further comprising cholesterol.

11. Further, it contains a phospholipid, and preferably dilauroyl phosphatidylcholine (DLPC), dimyristoyl phosphatidylcholine (DMPC), distearoyl phosphatidylcholine (DSPC), dioleoyl phosphatidylcholine (DOPC), dipalmitoyl phosphatidylcholine (DPPC), dimyristoyl phosphatidylglycerol (DMPG), distearoyl phosphatidylglycerol (DSPG), dioleoyl phosphatidylglycerol (DOPG), dipalmitoyl phosphatidylglycerol (DPPG), dimyristoyl phosphatidylserine (DMPS), 11. The liposome composition according to claim 9 or 10, comprising distearoyl phosphatidylserine (DSPS), dioleoyl phosphatidylserine (DOPS), dipalmitoyl phosphatidylserine (DPPS), dioleoyl phosphatidylethanolamine (DOPE), dipalmitoyl phosphatidylethanolamine (DPPE), dimyristoyl phosphatidylethanolamine (DMPE), distearoyl phosphatidylethanolamine (DSPE) or dielaidoyl phosphatidylethanolamine, more preferably DPPC.

12. The liposome composition according to any one of claims 9 to 11, further comprising a polyethylene glycolated phospholipid, preferably DLPE-PEG, DPPE-PEG, DMPE-PEG or DSPE-PEG, more preferably DSPE-PEG.

13. The liposome composition according to any one of claims 9 to 12, further comprising at least one therapeutic agent and / or at least one diagnostic agent.

14. comprising at least one therapeutic agent; The liposome composition of claim 13 , wherein the therapeutic agent is an anticancer agent.

15. The liposome composition according to claim 14, wherein the anticancer drug is selected from monomethyl auristatin E, monomethyl auristatin F, ibrutinib, acalabrutinib, zanubrutinib, doxorubicin, mitomycin-C, mitomycin-A, daunorubicin, aminopterin, actinomycin, bleomycin, 9-aminocamptothecin, N8-acetylspermidine, 1-(2-chloroethyl)-1,2-dimethanesulfonylhydrazide, Yunnanmycin, gemcitabine, cytarabine, dolastatin, dacarbazine, 5-fluorouracil, paclitaxel, docetaxel, gemcitabine, cytarabine, 6-mercaptopurine, vincristine, cisplatin, oxaliplatin, and PARP inhibitors.

16. The liposome composition of claim 15, wherein the anticancer drug is selected from PARP inhibitors, preferably olaparib, niraparib, rucaparib, fluzoparib, pamiparib, veliparib, talazoparib, and more preferably olaparib.

17. comprising at least one diagnostic agent, The diagnostic agent 64 The liposome composition of claim 13, which is Cu-NOTA-PEG2000-DSPE.

18. Use of the liposome composition according to any one of claims 9 to 17 in medicine.

19. Use of a liposomal composition according to any one of claims 9 to 17 for delivering at least one therapeutic agent and / or at least one diagnostic agent.